



MINUTES

# PMCN Work Group Meeting

Chair: Steven Verberckmoes

6 October 2016, 10:45 – 11:15

Metals Conference Centre  
Rue du Duc 100, Brussels (Belgium)



## 1. Welcome and Introduction

### 1.1. Reminder on Confidentiality and Competition Law

Participants are reminded on their obligation to comply with confidentiality and competition laws. All participants to the meeting are acting as moderators in this respect.

### 1.2. Tour de table and apologies

The list of participants is available in Annex 1.

### 1.3. Objectives, previous WG meeting minutes' approval, agenda approval

The objectives of the meeting are to update Members of the Precious Metal Cyanides ("PMCN") Work Group ("the WG") on the current status of the different phases of the project, to exchange critical information on the elements necessary to timely progress in the making of the registration dossier, and to agree on the next steps for its finalisation. The slides presented during the meeting are available in Annex 2.

The draft agenda is approved as distributed and is available in Annex 1.

The minutes of the WG meeting on April 19, 2016 are approved.

### 1.4. Status of actions

The status of actions that were agreed at the last PMCN meeting(s) are presented on slides 7 of the meeting's slide deck (Annex 2). All actions were completed.

## 2. Phase I

### 2.1. Inventory and latest classifications

No changes to the classification were made.

## 3. Phase III: Testing programme

### 3.1. Progress testing programme $KAg(CN)_2$

Second phase of the tox testing programme with  $KAg(CN)_2$  is almost finalised and awaiting the final reports of the OECD 422 and OECD 490.

For the combined repeated dose toxicity study (OECD 422), no toxicity was observed at the highest dose level of 10 mg/kg bw/day, even though this dose is already quite close to the LD50 of 21 mg/kg bw. During the dose range finding, it was already observed that the dose response curve is very steep. An extra statement will be included in the final report elaborating on this observation, to support the validity of the study. The WG was asked during the meeting to provide feedback on the OECD 422



report and to confirm that the formulation stability testing isn't needed to have a full valid study. [A35]  
WCA will be asked to start drafting the DNELs using the highest dose as worst case scenario.

For the *in vitro* mammalian gene mutation study (OECD 490) a clear positive result was observed. Therefore a testing proposal for an *in vivo* test has to be drafted. As there are different test possibilities to consider for this proposal, WCA will be asked to formulate a reasoning which further test would be the most suitable. [A36]

## 4. Phase IV: Testing programme

Not discussed, as the drafting of the DNELs is still to be initiated for  $\text{KAg}(\text{CN})_2$ .

## 5. Phase V: Dossier finalisation

Both  $\text{AgCN}$  and  $\text{KAu}(\text{CN})_2$  dossiers have been finalised and approved over the summer.  $\text{KAg}(\text{CN})_2$  has already been approved by the LR and co-registrants will receive in the coming week all necessary information to complete their submission. For  $\text{AgCN}$  the LR will submit the dossier in the coming weeks.

$\text{KAg}(\text{CN})_2$  are still on schedule for registration in Q3 2017. The main bottleneck in the timing will be the drafting of the occupational exposure scenarios, which will probably only start in February 2017. As EBRC requests that all necessary documents are provided timely, the WG is urged to review DNEL documents within the agreed deadline.

## 6. Budget

The 2017 budget consists mainly of rebuilding the project reserves, human resources and the remaining occupational exposure work for  $\text{KAg}(\text{CN})_2$ .

## 7. AOB

As we are nearing the 2018 deadline, most of the compounds have already been registered. For the next PMCN WG meetings only updates related to the  $\text{KAg}(\text{CN})_2$  dossier will be discussed and therefore the format of the meeting is up for discussion. Instead of having a face-to-face meeting, the WG meeting can be held by conference call in March to give the most important updates. If urgent matters arise a face-to-face meeting could be scheduled *ad hoc*.



## 8. List of actions

Table 1. Actions agreed on at the PMCN WG meeting of 19 April '16

[A]	WHAT	WHO	WHEN
35	Review of OECD 422 with potassium dicyanoargentate and formulation stability amendment.	WG	14 Oct '16
36	Drafting of a testing proposal for the gene mutation endpoint of potassium dicyanoargentate.	WCA	Apr '16

## 9. List of Annexes

1. Approved Agenda and List of participants
2. Slides presented during the meeting